- $61.94m
- $21.07m
- $0.92m
- 49
- 28
- 15
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 1.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 60.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.97% | ||
| Return on Equity | -39.48% | ||
| Operating Margin | -3442.37% | ||
Financial Summary
| Year End 31st Jul | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.8 | 0.41 | 0.28 | 0.64 | 0.92 | n/a | n/a | -28.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.
Directors
- Howard Jonas CHM (65)
- Patrick Fabbio PRE (54)
- William Conkling CEO (50)
- Ashok Marin OTH (53)
- David Polinsky OTH (50)
- Stephen Greenberg LED (77)
- Rachel Jonas DRC (28)
- Shannon Klinger DRC (50)
- Ameet Mallik DRC (49)
- Mark McCamish DRC (69)
- Boris Pasche IND (60)
- Michael Weiss IND (70)
- Last Annual
- July 31st, 2025
- Last Interim
- October 31st, 2025
- Incorporated
- July 27th, 2017
- Public Since
- March 12th, 2018
- No. of Shareholders
- 290
- No. of Employees
- 21
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 52,493,934.75
- Address
- 520 Broad Street, NEWARK, 07120
- Web
- https://rafaelholdings.com
- Phone
- +1 2126581450
- Auditors
- CohnReznick LLP
Upcoming Events for RFL
Q3 2026 Rafael Holdings Inc Earnings Release
Similar to RFL
Abbvie
New York Stock Exchange
AstraZeneca
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
FAQ
What is the Rafael Holdings share price?
As of Today at 03:49 UTC, shares in Rafael Holdings are trading at $1.18. This share price information is delayed by 15 minutes.
How has the Rafael Holdings share price performed this year?
Shares in Rafael Holdings last closed at $1.18 and the price had moved by -40.45% over the past 365 days. In terms of relative price strength the Rafael Holdings share price has underperformed the S&P500 Index by -46.71% over the past year.
What are the analyst and broker recommendations for Rafael Holdings?
There is no consensus recommendation for this security.
Find out moreWhat is the Rafael Holdings dividend yield?
Rafael Holdings does not currently pay a dividend.
Does Rafael Holdings pay a dividend?
Rafael Holdings does not currently pay a dividend.
When does Rafael Holdings next pay dividends?
Rafael Holdings does not currently pay a dividend.
How do I buy Rafael Holdings shares?
To buy shares in Rafael Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rafael Holdings?
As of the previous close price of $1.18, shares in Rafael Holdings had a market capitalisation of $61.94m.
Where are Rafael Holdings shares listed?
Here are the trading details for Rafael Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: RFL
What kind of share is Rafael Holdings?
Based on an overall assessment of its quality, value and momentum Rafael Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rafael Holdings share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Rafael Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rafael Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -31.71%.
As of the last closing price of $1.18, shares in Rafael Holdings were trading -20.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rafael Holdings PE Ratio?
The Rafael Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rafael Holdings?
Rafael Holdings' management team is headed by:
- Howard Jonas - CHM
- Patrick Fabbio - PRE
- William Conkling - CEO
- Ashok Marin - OTH
- David Polinsky - OTH
- Stephen Greenberg - LED
- Rachel Jonas - DRC
- Shannon Klinger - DRC
- Ameet Mallik - DRC
- Mark McCamish - DRC
- Boris Pasche - IND
- Michael Weiss - IND